TITLE

CROATIAN INTERNATIONAL PUBLICATIONS

AUTHOR(S)
Lukić, Ivan Krešimir
PUB. DATE
June 2010
SOURCE
Croatian Medical Journal;Jun2010, Vol. 51 Issue 3, p279
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The article presents abstracts on medical topics which include the effect of propofol on the diaphragm of rats, analysis of high-density single nucleotide polymorphism array and screening of ASXL1 gene mutation in chronic myeloid leukemia during the propagation of disease, and bone cell activity in men with idiopathic osteoporosis.
ACCESSION #
52291707

 

Related Articles

  • Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ammatuna, Emanuele; Eefting, Matthias; Lom, Kirsten; Kavelaars, François; Valk, Peter; Touw, Ivo // Annals of Hematology;Jun2015, Vol. 94 Issue 6, p1079 

    A correction to the article "Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib" that was published in the March 31, 2015 issue is presented.

  • Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ammatuna, Emanuele; Eefting, Matthias; Lom, Kirsten; Kavelaars, François; Valk, Peter; Touw, Ivo // Annals of Hematology;May2015, Vol. 94 Issue 5, p879 

    A letter to the editor is presented on the case of a patient with atypical chronic myeloid leukemia and concomitant colony-stimulating factor 3 receptor gene T618I and SET binding protein-1 mutations who did not respond to ruxolitinib.

  • Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses. Jiye, A.; Sixuan Qian; Guangji Wang; Bei Yan; Sujiang Zhang; Qing Huang; Lingna Ni; Weibin Zha; Linsheng Liu; Bei Cao; Ming Hong; Hanxin Wu; Hua Lu; Jian Shi; Mengjie Li; Jianyong Li // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure. Metabonomic and genomic profiling of patients' responses to drug interventions can provide...

  • Novel Resistance Mechanism To Iressa, Tarceva Found.  // Bioworld Week;5/7/2007, Vol. 15 Issue 19, p1 

    The article reports on the ineffective of cancer drugs due to a second mutation in the original target in the U.S. It states that secondary mutations in the bcr-abl kinase that is hyperactive in chronic myelogenous leukemia, and targeted by Gleevec, lead to a relapse rate of 17 percent over five...

  • The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT. Langabeer, S E; McCarron, S L; Haslam, K; O'Donovan, M T; Conneally, E // Bone Marrow Transplantation;Jun2014, Vol. 49 Issue 6, p843 

    A letter to the editor is presented regarding a case of a 60-year-old woman with normal karyotype and chronic myelogenous leukemia (CML), whose medical examination has detected a CSF3R T618I mutation.

  • Resistant mutations in CML and Ph+ALL - role of ponatinib. Miller, Geoffrey D.; Bruno, Benjamin J.; Lim, Carol S. // Biologics: Targets & Therapy;2014, Vol. 8 Issue 10, p243 

    In 2012, ponatinib (Iclusig®), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug Administration for use in resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive...

  • Dasatinib/imatinib/nilotinib.  // Reactions Weekly;May2014, Vol. 1499 Issue 1, p13 

    An abstract of the article "Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure," by L.-Y. Shih and colleagues is presented.

  • Report of patients with chronic myeloid leukemia Kidwai Memorial Institute of Oncology, Bangalore over 15 years. Babu, Govind // Indian Journal of Medical & Paediatric Oncology;Jul-Sep2013, Vol. 34 Issue 3, p196 

    Kidwai Memorial Institute of Bangalore is one of the most comprehensive and major regional cancer center. It was established in 1974 and caters population not only from Karnataka, but also from Tamil Nadu, Andhra Pradesh. They presented the data of 540 patients out of which 95% patients were in...

  • Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. YaZhen Qin; ShanShan Chen; Bin Jiang; Qian Jiang; Hao Jiang; JinLan Li; LingDi Li; YueYun Lai; YanRong Liu; XiaoJun Huang // Annals of Hematology;Jan2011, Vol. 90 Issue 1, p47 

    To explore the characteristics of BCR-ABL kinase domain point mutations in Chinese chronic myeloid leukemia (CML) patients, a cohort of 127 patients with hematologic or cytogenetic resistance to imatinib are screened by direct sequencing. Mutations are found in 74 patients (58%). More patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics